Jane Street’s SELLAS Life Sciences SLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.03M Sell
243,500
-39,200
-14% -$175K ﹤0.01% 6440
2025
Q4
$1.07M Buy
282,700
+156,500
+124% +$304K ﹤0.01% 5990
2025
Q3
$203K Sell
126,200
-82,600
-40% -$147K ﹤0.01% 9662
2025
Q2
$457K Buy
208,800
+77,200
+59% +$118K ﹤0.01% 7093
2025
Q1
$142K Buy
131,600
+93,100
+242% +$111K ﹤0.01% 8643
2024
Q4
$40K Buy
38,500
+3,500
+10% +$4K ﹤0.01% 9023
2024
Q3
$43.8K Buy
35,000
+25,000
+250% +$30.6K ﹤0.01% 9199
2024
Q2
$11.9K Hold
10,000
﹤0.01% 9090
2024
Q1
$10.1K Buy
+10,000
New +$8.4K ﹤0.01% 8966
2022
Q1
Sell
-15,700
Closed -$87K 10963
2021
Q4
$87K Sell
15,700
-300
-2% -$2.27K ﹤0.01% 9311
2021
Q3
$147K Sell
16,000
-25,000
-61% -$232K ﹤0.01% 9077
2021
Q2
$455K Buy
+41,000
New +$400K ﹤0.01% 7415

Other funds holding SLS

Jane Street's SLS Position: Q1 2026 in Review

Jane Street sold out of SELLAS Life Sciences (SLS) in Q1 2026, closing a stake of 59,536 shares — an estimated $266K sold.

Jane Street first reported a position in SLS in Q3 2019 and held it in 10 quarters. The position peaked at $224K in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • Jane Street reported no remaining SELLAS Life Sciences position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 59,536 SELLAS Life Sciences shares in Q1 2026, an estimated $266K.
  • Jane Street first reported a position in SELLAS Life Sciences in Q3 2019 and held it in 10 quarters.
  • Jane Street's SELLAS Life Sciences position peaked at $224K in Q4 2025.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.